The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 01, 2016

Filed:

Jan. 22, 2010
Applicants:

Tina Møller Tagmose, Ballerup, DK;

Patrick William Garibay, Holte, DK;

Bírgítte Andersen, Malov, DK;

Henning Thøgersen, Farum, DK;

Birgit Wieczorek, Koebenhavn N, DK;

Inventors:

Tina Møller Tagmose, Ballerup, DK;

Patrick William Garibay, Holte, DK;

Bírgítte Andersen, Malov, DK;

Henning Thøgersen, Farum, DK;

Birgit Wieczorek, Koebenhavn N, DK;

Assignee:

Novo Nordisk A/S, Bagsvaerd, DK;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A01N 43/64 (2006.01); A61K 31/41 (2006.01); A01N 43/36 (2006.01); A61K 31/40 (2006.01); A01N 37/00 (2006.01); A61K 31/19 (2006.01); A61K 47/48 (2006.01); C07K 14/50 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48046 (2013.01); A61K 47/48215 (2013.01); A61K 47/48284 (2013.01); C07K 14/50 (2013.01); A61K 38/00 (2013.01);
Abstract

The present invention relates to Fibroblast Growth Factor 21 (FGF21), more in particular to derivatives of FGF21 compounds having an albumin binder of the formula A-B-C-D-E- covalently attached. The invention also relates to novel FGF21 analogues, as well as to the pharmaceutical use of these FGF21 derivatives and analogues, in particular for the treatment of diabetes, dyslipidemia, obesity, cardiovascular diseases, metabolic syndrome, and/or Non Alcoholic Fatty Liver Disease (NAFLD). The derivatives of the invention are protracted, e.g. capable of maintaining a low blood glucose level for a longer period of time, capable of increasing the in vivo half-life of FGF21, and/or result in a lower clearance of FGF21. The derivatives of the invention are preferably furthermore of an improved oxidative stability.


Find Patent Forward Citations

Loading…